
Glenmark Pharmaceuticals Ltd., a global pharmaceutical company, introduced a biosimilar of the anti-diabetic drug liraglutide named Lirafit in India. Approved by the Drug Controller General of India, the drug reduces therapy costs by around 70%. Lirafit, belonging to the GLP-1 RA drug class, aids glycaemic control in type 2 diabetes patients. Glenmark's entry into the injectable anti-diabetic market expands its diabetes therapy offerings, reflecting its commitment to affordable and effective treatments for diabetic patients. The move aligns with the rising prevalence of diabetes in India and the growing market for GLP-1 RA drugs.
Like
Save
Share